Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Actinium Pharmaceuticals Inc (ATNM)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$1.30-7.80%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ATNM yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improve cash flow from operations to reduce negative cash burn | Cash flow from operations also improved from -$7.6M to -$5.9M. | Broken | cash flow from operations worsens beyond -$5.9 million | Cash from operations: $-5.179M FY2026-Q2; GAAP. Published target: cash flow from operations >= -5.9 million USD. Target period is not explicitly aligned with this observation. Aug 7, 2026-5,179,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making clinical-stage biotechnology business, not an established earnings compounder. The multi-year view is currently intact, but management’s progress on listing compliance and Actimab-A remains mixed, and the evidence is limited.
ATNM is assessed as cheap versus peers, but confidence in that valuation model is low. The valuation score fell by 16.2 points recently, while the available evidence does not establish what specific expectations the market assumes.
Recent financial performance is strong relative to its industry, and the thesis state reflects that the business case remains intact. Near term, the chance of missing expectations is worth watching because the company is smaller and operates in an industry with a high miss rate; management has not yet reported restored listing compliance or substantive clinical progress in the supplied evidence.
The multi-year thesis depends on ATNM advancing Actimab-A, expanding manufacturing flexibility, and regaining compliance with NYSE American listing standards. Near term, weakening jobs data could weigh on cyclical names, while continued strength or weakness among healthcare bellwethers such as VRTX, REGN, and MRNA could reinforce or weaken the sector tailwind.
Over the next 1 to 3 years, strong recent performance supports an intact thesis, but losses, high risk, and limited proof of execution make the outcome uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Actinium aims to meet NYSE listing rules by improving stockholders' equity above $4 million. |
| Broken |
| stockholders' equity falls below $4 million |
Total equity: $30.302M FY2026-Q2; GAAP. Published target: >=4.0 million USD. Target period is not explicitly aligned with this observation. Aug 7, 202630,302,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain stable leadership after CFO transition | A supporting condition in Actinium Pharmaceuticals Inc's published investment case. The stated target is no further major executive departures in next 4 quarters. | Under Pressure | additional key executive departures occur | 1 additional departure vs 0 allowed CFO departure confirmed in Feb 2026; new external CFO hired in Oct 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating losses toward sustainable levels | These steps show progress toward financial stability despite current losses. | Intact | operating loss worsens beyond -$5.9 million | Operating income: $27.565M FY2026-Q2; GAAP. Published target: operating loss <= -5.9 million USD. Target period is not explicitly aligned with this observation. Aug 7, 202627,565,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.67 → $-0.57 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.67 | $19,390,000 | 2 / 3 |
| 2026-07-25 | $-0.67 | $19,390,000 | 2 / 3 |
| 2026-07-26 | $-0.67 | $19,390,000 | 2 / 3 |
| 2026-07-27 | $-0.67 | $19,390,000 | 2 / 3 |
| 2026-07-28 | $-0.67 | $19,390,000 | 2 / 3 |
| 2026-07-29 | $-0.67 | $19,390,000 | 2 / 3 |
| 2026-07-30 | $-0.67 | $19,390,000 | 2 / 3 |
| 2026-07-31 | $-0.35 | $12,926,670 | 2 / 3 |
| 2026-08-01 | $-0.35 | $12,926,670 | 2 / 3 |
| 2026-08-02 | $-0.35 | $12,926,670 | 2 / 3 |
| 2026-08-03 | $-0.35 | $12,926,670 | 2 / 3 |
| 2026-08-04 | $-0.35 | $12,926,670 | 2 / 3 |
| 2026-08-05 | $-0.35 | $12,926,670 | 2 / 3 |
| 2026-08-06 | $-0.35 | $12,926,670 | 2 / 3 |
| 2026-08-07 | $-0.67 | $19,390,000 | 2 / 3 |
| 2026-08-08 | $-0.35 | $12,926,670 | 2 / 3 |
| 2026-08-09 | $-0.35 | $12,926,670 | 2 / 3 |
| 2026-08-10 | $-0.35 | $12,926,670 | 2 / 3 |
| 2026-08-11 | $-0.35 | $12,926,670 | 2 / 3 |
| 2026-08-12 | $-0.38 | $19,390,000 | 2 / 2 |
| 2026-08-13 | $-0.38 | $19,390,000 | 2 / 2 |
| 2026-08-14 | $-0.67 | $19,390,000 | 2 / 3 |
| 2026-08-15 | $-0.67 | $19,390,000 | 2 / 2 |
| 2026-08-16 | $-0.67 | $19,390,000 | 2 / 2 |
| 2026-08-17 | $-0.67 | $19,390,000 | 2 / 2 |
| 2026-08-18 | $-0.67 | $19,390,000 | 2 / 2 |
| 2026-08-19 | $-0.67 | $19,390,000 | 2 / 2 |
| 2026-08-20 | $-0.67 | $19,390,000 | 2 / 2 |
| 2026-08-21 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-08-22 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-08-23 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-08-24 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-08-25 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-08-26 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-08-27 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-08-28 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-08-29 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-08-30 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-08-31 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-01 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-02 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-03 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-04 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-05 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-06 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-07 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-08 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-09 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-10 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-11 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-12 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-13 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-14 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-15 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-16 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-17 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-18 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-19 | $-0.53 | $19,390,000 | 2 / 2 |
| 2026-09-20 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-09-21 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-09-22 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-09-23 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-09-24 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-09-25 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-09-26 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-09-27 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-09-28 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-09-29 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-09-30 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-01 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-02 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-03 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-04 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-05 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-06 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-07 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-08 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-09 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-10 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-11 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-12 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-13 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-14 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-15 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-16 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-17 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-18 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-19 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-20 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-21 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-22 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-23 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-24 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-25 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-26 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-27 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-28 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-29 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-30 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-10-31 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-11-01 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-11-02 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-11-03 | $-0.57 | $19,390,000 | 2 / 3 |
| 2026-11-04 | $-0.57 | $19,390,000 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.